Travere Therapeutics

Rule Changes

Awaiting FDA decision on sparsentan for FSGS

No FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) has ever existed. For the 40,000 Americans with this rare kidney disease—which drives half to kidney failure within a decade—the only options have been off-label immunosuppressants with mixed results.

Updated May 21